Skip to main content

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Terminated · Phase 2 · NCT05443724

Conditions: Schizophrenia

At a glance

Research payments reported, 2025
$4.7M
U.S. investigators named
61
Sites paid
58
Planned or actual enrollment
698

About the trial

Sponsor
AbbVie
Tested
Emraclidine 30 mg (drug)
Dates
Started 2022-09-01; completion 2025-06-25
Results posted
Yes

The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.

From ClinicalTrials.gov, last updated 2026-08-21. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $4.7M in research payments for this study in 2025 (583 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Collaborative Neuroscience Research LLC $633,228
  • Envision Trials LLC $321,686
  • Innovative Clinical Research Inc $307,342
  • Omega Clinical Trials LLC $265,923
  • Galiz Research LLC $227,779
  • Advanced Research Center Inc $225,531
  • Cnri Los Angeles LLC $173,562
  • Schuster Medical Research Institute $172,418
  • Premier Clinical Research Inst $161,921
  • Premier Clinical Research Institute Inc $159,206
  • Neuro Behavioral Clinical Research Inc $145,095
  • Interspond LLC $144,107
  • Ima Evaluations LLC $142,201
  • Neurobehavioral Research Inc $119,192
  • South Florida Research Phase I Iv Inc $109,695
  • Collaborative Neuroscience Res $104,525
  • New Access Research and Medical Center $87,069
  • Clinical Trial Network $85,826
  • Srsd Inc $85,435
  • Insite Clinical Research LLC $80,271
  • Elligo Health Research Inc $71,391
  • Sunwise Clinical Research LLC $70,282
  • Schuster Medical Research Inst $63,214
  • Health Synergy Clinical Research LLC $60,787
  • Erg Clinical Research New York $59,573
  • Columbus Clinical Services LLC $53,431
  • Northwestern University $43,155
  • Pns Clinical Research LLC $37,415
  • Proscience Research Group LLC $35,710
  • Inspira Mental Health Management Inc $35,702
  • Artemis Headlands LLC $31,964
  • Keralty Hospital, FL $27,578
  • Mary Ann Knesevich MD PA $26,711
  • Cbh Health LLC $25,674
  • Erg Holding Company LLC $24,956
  • Community Clinical Research Inc $23,682
  • Cenexel Iresearch LLC $22,011
  • Advanced Discovery Research LLC $20,516
  • Clinitiative Health Research $20,133
  • Tandem Clinical Research LLC $18,801
  • Clinical Innovations Inc $18,744
  • Pharmaseek LLC $17,813
  • New Hope Clinical Research Inc $17,701
  • Regents of the University of California $14,374
  • Cnri San Diego LLC $12,956
  • Alexian Brothers Health System $9,984
  • University of California Davis Medical Center, CA $9,149
  • Atlanta Center for Medical Research Inc $7,581
  • Mohd A Malik Psych Care Consultants Research $6,523
  • Yale University $6,500
  • Precise Clinical Research Inc $6,283
  • Psychiatric Consultants PC $5,574
  • Pillar Clinical Research LLC $4,618
  • Barbara Diaz Hernandez MD Research Inc $3,829
  • Catalina Research Institute LLC $3,659
  • Emerge Medical Research Inc $2,600
  • Lsb Research Group LLC $1,095
  • Research Centers of America LLC $407

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.